search
Back to results

Neoadjuvant Sorafenib Therapy Prior to Laser Ablation for Hepatocellular Carcinoma (LANEX)

Primary Purpose

Hepatocellular Carcinoma

Status
Completed
Phase
Phase 2
Locations
Italy
Study Type
Interventional
Intervention
Sorafenib
laser ablation (LA)
Sponsored by
Cardarelli Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hepatocellular Carcinoma focused on measuring hepatocellular carcinoma, sorafenib, laser ablation

Eligibility Criteria

18 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age 18-80 years
  • ECOG = 0 or 1
  • No liver decompensation (Child-Pugh <8), bilirubin <3mg/dL
  • Patients with unresectable HCC or who refused surgery
  • Confirmed HCC by pathology or by AASLD imaging guidelines
  • At least one HCC nodule (index tumor) accurately measured as 4-8cm in diameter on baseline imaging
  • No prior therapy for the index tumor
  • No prior systemic treatment for HCC within 4 weeks of study entry
  • LA clinically indicated for index tumor
  • Hemoglobin >9.0 g/dl; Platelet count correctable to >50,000/mm3; INR correctable to <2.0.

Exclusion Criteria:

  • Other severe concomitant diseases that may reduce life expectancy
  • Participants currently receiving any other study agents
  • Cancer vascular invasion or extrahepatic metastasis
  • Uncontrolled hypertension
  • Thrombotic events or myocardial infarction within the past 6 months
  • Hemorrhage/bleeding event within 4 weeks
  • Evidence of severe or uncorrectable bleeding diathesis or coagulopathy
  • Contraindication to or inability to undergo the LA procedure
  • Human immunodeficiency virus (HIV) infection
  • Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results
  • Any condition that is unstable or which could jeopardize the safety of the patient and his/her compliance in the study.

Sites / Locations

  • UOSC Epatologia - Cardarelli Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Group A

Group B

Arm Description

Patients who undergo to LA without sorafenib pretreatment

Patients who are treated with sorafenib before LA

Outcomes

Primary Outcome Measures

Effectiveness of sorafenib in increasing the effectiveness of laser ablation (LA)
Measures: complete tumor ablation rate (according to the mRECIST), time-to-recurrence (in complete response subgroup), time-to-progression (in partial response subgroup).

Secondary Outcome Measures

Safety of sorafenib treatment prior to LA.
Measure: incidence and grade of adverse events in patients treated with sorafenib (group B)
Survival in the two treatment groups
Measured from the date of LA until the date of death or last visit

Full Information

First Posted
January 5, 2012
Last Updated
March 4, 2017
Sponsor
Cardarelli Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT01507064
Brief Title
Neoadjuvant Sorafenib Therapy Prior to Laser Ablation for Hepatocellular Carcinoma
Acronym
LANEX
Official Title
Randomized Controlled Phase II Trial Of Neoadjuvant Sorafenib Therapy Prior to Thermal Ablation for Hepatocellular Carcinoma More Than 4 cm in Size
Study Type
Interventional

2. Study Status

Record Verification Date
March 2017
Overall Recruitment Status
Completed
Study Start Date
January 2012 (undefined)
Primary Completion Date
September 2015 (Actual)
Study Completion Date
September 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Cardarelli Hospital

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to determine whether neoadiuvant therapy with sorafenib increases the efficacy of thermal ablation in inducing the necrosis of hepatocellular carcinoma.
Detailed Description
BACKGROUND AND AIM Image-guided laser ablation (LA), minimally invasive procedure, is a potentially viable treatment option for achieving focal thermal destruction of hepatocellular carcinoma (HCC) that cannot be treated with surgery. Both techniques are effective for the destruction of small (<3 cm) tumors, but the success rate for index tumors larger than 4 cm in diameter is lower. A cause of the difficulty in treating larger tumors is represented by the heat-sink effect of tumor blood flow that limits the size of tumor ablation by drawing heat away from the tumor nodule. Surgical (Pringle maneuver) and endovascular (transarterial chemoembolization) techniques have been used to reduce the tumor blood flow during or before thermal ablation, but these techniques require invasive procedures that may decrease the patient acceptance and increase the risk of complications. Sorafenib is a multikinase inhibitor that has been approved for the treatment of advanced HCC. One of the main effect of this drug is to block vascular endothelial growth factor (VEGF) pathway, Flt-3, c-KIT, and fibroblast growth factor receptor 1, that have been shown to mediate tumor angiogenesis, reducing intratumoral blood flow. An experimental study in mice with renal cell carcinoma implanted subcutaneously, showed that treatment with sorafenib before ablation resulted in markedly decreased cancer microvessel density and significantly larger zones of radiofrequency-induced coagulation necrosis (1). The purpose of this study is to determine if sorafenib improves the effectiveness of laser ablation (LA) for the treatment of HCC larger than 4cm in size. 1. Hakimé A, Hines-Peralta A, Peddi H, Atkins MB, Sukhatme VP, Signoretti S, Regan M, Goldberg SN. Combination of Radiofrequency Ablation with Antiangiogenic Therapy for Tumor Ablation Efficacy: Study in Mice. Radiology 2007, 244, 464-470. STUDY DESIGN Participants will be randomized to receive either sorafenib (400mg twice a day) or placebo continuously for 4 weeks (on days 1-28). LA will be performed on day 29. On days 0 and 28, and 1, 6, and 12 months after LA, patients will undergo to a physical exam. Adverse events will be recorded using a pre-planned questionnaire in accordance with the "common toxicity criteria". Occurrence and characteristics of postablation syndrome will also be recorded. During a six-month period, if clinically indicated LA procedures preceded by a four-week sorafenib treatment, may be repeated up to three times. Laboratory values will be assessed on days 0 and 28, and 1, 6, and 12 months after the first LA procedure. Upper gastrointestinal endoscopy will be done before starting drug treatment. A tumor biopsy will be obtained at the time of the first LA. A CT or MRI scan will be performed at the time of inclusion in the study, at 1, 6, and 12 months after LA.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hepatocellular Carcinoma
Keywords
hepatocellular carcinoma, sorafenib, laser ablation

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
40 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Group A
Arm Type
Active Comparator
Arm Description
Patients who undergo to LA without sorafenib pretreatment
Arm Title
Group B
Arm Type
Experimental
Arm Description
Patients who are treated with sorafenib before LA
Intervention Type
Drug
Intervention Name(s)
Sorafenib
Other Intervention Name(s)
Nexavar
Intervention Description
tablets 200mg dosage: 400mg bid duration: 4 weeks
Intervention Type
Procedure
Intervention Name(s)
laser ablation (LA)
Intervention Description
For LA, we use a commercially available system (Echolaser XVG system, Esaote El.En., Florence, Italy) and four optical fibers,inserted into the tumor through four 21-gauge needles. The tips of the needles will be positioned at a distance of 15mm from each other. When, after LA treatments, CT or MRI findings show a residual nodule activity of 10% or less, percutaneous ethanol injection may be done. If the residual activity is of 50% or more transarterial chemoembolization may be used.
Primary Outcome Measure Information:
Title
Effectiveness of sorafenib in increasing the effectiveness of laser ablation (LA)
Description
Measures: complete tumor ablation rate (according to the mRECIST), time-to-recurrence (in complete response subgroup), time-to-progression (in partial response subgroup).
Time Frame
1 year
Secondary Outcome Measure Information:
Title
Safety of sorafenib treatment prior to LA.
Description
Measure: incidence and grade of adverse events in patients treated with sorafenib (group B)
Time Frame
6 months
Title
Survival in the two treatment groups
Description
Measured from the date of LA until the date of death or last visit
Time Frame
2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 18-80 years ECOG = 0 or 1 No liver decompensation (Child-Pugh <8), bilirubin <3mg/dL Patients with unresectable HCC or who refused surgery Confirmed HCC by pathology or by AASLD imaging guidelines At least one HCC nodule (index tumor) accurately measured as 4-8cm in diameter on baseline imaging No prior therapy for the index tumor No prior systemic treatment for HCC within 4 weeks of study entry LA clinically indicated for index tumor Hemoglobin >9.0 g/dl; Platelet count correctable to >50,000/mm3; INR correctable to <2.0. Exclusion Criteria: Other severe concomitant diseases that may reduce life expectancy Participants currently receiving any other study agents Cancer vascular invasion or extrahepatic metastasis Uncontrolled hypertension Thrombotic events or myocardial infarction within the past 6 months Hemorrhage/bleeding event within 4 weeks Evidence of severe or uncorrectable bleeding diathesis or coagulopathy Contraindication to or inability to undergo the LA procedure Human immunodeficiency virus (HIV) infection Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results Any condition that is unstable or which could jeopardize the safety of the patient and his/her compliance in the study.
Facility Information:
Facility Name
UOSC Epatologia - Cardarelli Hospital
City
Napoli
ZIP/Postal Code
80131
Country
Italy

12. IPD Sharing Statement

Learn more about this trial

Neoadjuvant Sorafenib Therapy Prior to Laser Ablation for Hepatocellular Carcinoma

We'll reach out to this number within 24 hrs